Consolidated statement of cash flows
for the year ended 30 June 2016
| Download (EXCEL) |
| Group | Company | |||||||||
| Note | 30 June 2016 R'000 |
30 June 2015 R'000 |
30 June 2016 R'000 |
30 June 2015 R'000 |
||||||
| Cash flows from operating activities | ||||||||||
| Cash receipts from customers | 3 549 618 | 2 382 459 | 873 | 82 | ||||||
| Cash paid to suppliers and employees | (3 155 767) | (1 985 463) | (62 107) | (13 341) | ||||||
| Cash generated from operations | 28 | 393 851 | 396 996 | (61 234) | (13 259) | |||||
| Finance income | 25 | 32 386 | 28 799 | 12 415 | 5 680 | |||||
| Finance costs | 25 | (4 547) | (9 997) | (4 836) | (6 724) | |||||
| Taxation paid | 29 | (102 584) | (92 958) | – | – | |||||
| Dividends received | – | – | 73 120 | 160 340 | ||||||
| Dividends received from associates | 10 | 4 112 | 1 841 | – | – | |||||
| Dividends paid | 30 | (121 963) | (130 999) | (121 963) | (130 999) | |||||
| Dividends paid to minority shareholders | 30 | (9 522) | (14 446) | – | – | |||||
| Net cash inflow from operating activities | 191 733 | 179 236 | (102 498) | 15 038 | ||||||
| Cash flows from investing activities | ||||||||||
| Proceeds on disposal of intangible assets | 390 | – | – | – | ||||||
| Purchase of plant and equipment | 6 | (113 444) | (45 552) | – | – | |||||
| Purchase of intangible assets | 8 | (164 862) | (190 074) | – | – | |||||
| Proceeds on disposal of tangible assets | 11 595 | 7 205 | – | – | ||||||
| Purchase of other investments | – | (715) | – | – | ||||||
| Purchase of Activo Health (associate) | 10 | (8 957) | – | – | – | |||||
| Obtaining control of Pharmacy Direct, Curasana and Glen Eden | 4 | 41 747 | – | – | – | |||||
| Purchase of financial assets | (411 934) | – | (411 934) | – | ||||||
| Redemption of Jasco preference shares | – | 90 000 | – | 90 000 | ||||||
| Decrease in investment and loans | – | 234 | – | – | ||||||
| Net cash (outflow)/inflow from investing activities | (645 465) | (138 902) | (411 934) | 90 000 | ||||||
| Cash flows from financing activities | ||||||||||
| Shares issued to Sanlam by subsidiary | 703 000 | – | 703 000 | – | ||||||
| Decrease in borrowings | (61 224) | (96 599) | (61 224) | – | ||||||
| AfroCentric Health minority buy-out | (122 164) | – | – | – | ||||||
| Decrease in loans from Group companies | (31 686) | – | (15 471) | (102 618) | ||||||
| Net cash inflow from financing activities | 487 926 | (96 599) | 626 305 | (102 618) | ||||||
| Net increase/(decrease) in cash and cash equivalents | 34 194 | (56 265) | 111 873 | 2 420 | ||||||
| Effect of foreign exchange rate changes | 4 823 | 867 | – | – | ||||||
| Cash and cash equivalents at the beginning of the period | 334 051 | 389 449 | 34 011 | 31 591 | ||||||
| Cash and cash equivalents at the end of year | 9.6 | 373 068 | 334 051 | 145 884 | 34 011 | |||||